Nitroglycerin (Nitrostat, Nitrogard, Nitrolingual, Nitro-Bid, Nitrol, Nitro-Dur, Transderm-Nitro)

Category:

  • Miscellaneous

Description:

  • Antianginal (venous (predominantly) and arterial dilator)

Indications:

  • Acute angina, angina prophylaxis, perioperative hypertension, CHF associated with MI

  • Unresponsive angina pectoris

Contraindications:

  • Severe anemia, closed-angle glaucoma, postural hypotension, early MI, head trauma

  • Cerebral hemorrhage, hypotension, uncorrected hypovolemia, inadequate cerebral circulation, increased intracrainial pressure, constrictive pericarditis, pericardial tamponade (IV)

Precautions:

  • Pregnancy category C; may use SL for angina

  • Early days of MI, hypertrophic cardiomyopathy, severe hepatic/renal disease

  • Children, glaucoma, abrupt withdrawal, continuous delivery

Adverse Reactions (Side Effects):

  • CNS: agitation, anxiety, apprehension, confusion, dizziness, dyscoordination, headache, hypoesthesia, hypokinesia, insomnia, nervousness, nightmares, vertigo, restlessness

  • CV: atrial fibrillation, collapse, crescendo angina, dysrhythmias, palpitations, postural hypotension, PVC’s, rebound hypertension, retrosternal discomfort, syncope, tachycardia

  • GI: abdominal pain, diarrhea, dyspepsia, fecal incontinence, nausea, tenesmus

  • GU: dysuria, impotence, urinary frequency

  • HEME: hemolytic anemia, methemoglobinemia

  • SKIN: allergic reactions (ointment), contact dermatitis (transdermal), crusty skin lesions, cutaneous vasodilation with flushing, exfloiative dermatitis, rash, sweating

Dosage:

Administered orally (spray, capsule, SL tablet, EC tablet, buccal tablet), topically (transdermal, ointment), and intravenously

  • Adult: 

    • BUCCAL 1mg every 3-5 hours while awake initially, titrate dosage upward if angina occurs with tablet in place

    • PO 2.5-9mg 2-4 times daily, up to 26mg 4 times daily;

    • IV 5 mcg/min via continuous infusion, increase by 5 mcg/min every 3-5 minutes to 20 mcg/min; if no response, increase by 10 mcg/min every 3-5 minutes up to 200 mcg min;

    • TOP 1-2 inches every 8 hours, up to 4-5 inches every 4 hours

    • TRANSDERMAL 0.2-0.4 mg/hr initially, titrate to 0.4-0.8 mg/hr; apply new patch daily; tolerance is minimized by removing patch for 10-12 hours daily

    • SL 0.2-0.6mg every 5 minutes for a max of 3 doses in 15 minutes; may also use prophylactically 5-10 minutes prior to activities that provoke angina attack

  • Child: 

    • IV 0.25-0.5 mcg/kg/min, titrate by 0.5-1 mcg/kg/min every 3-5 minutes as needed; usual dose 1-3 mcg/kg/min; max 20 mcg/kg/min

 

Special Considerations:

  • 10-12 hour drug-free intervals prevent development of tolerance

 

 

Home  ·  Military Medicine  ·  Sick Call  ·  Basic Exams  ·  Medical Procedures  ·  Lab and X-ray  ·  The Pharmacy  ·  The Library  ·  Equipment  ·  Patient Transport  ·  Medical Force Protection  ·  Operational Safety  ·  Operational Settings  ·  Special Operations  ·  Humanitarian Missions  ·  Instructions/Orders  ·  Other Agencies  ·  Video Gallery  ·  Forms  ·  Web Links  ·  Acknowledgements  ·  Help  ·  Feedback

Approved for public release; Distribution is unlimited.

The information contained here is an abbreviated summary. For more detailed and complete information, consult the manufacturer's product information sheets or standard textbooks.

Source: Operational Medicine 2001, Health Care in Military Settings, NAVMED P-5139, May 1, 2001, Bureau of Medicine and Surgery, Department of the Navy, 2300 E Street NW, Washington, D.C., 20372-5300.

Bureau of Medicine and Surgery
Department of the Navy
2300 E Street NW
Washington, D.C
20372-5300

Operational Medicine
 Health Care in Military Settings
CAPT Michael John Hughey, MC, USNR
NAVMED P-5139
  January 1, 2001

United States Special Operations Command
7701 Tampa Point Blvd.
MacDill AFB, Florida
33621-5323

*This web version is provided by The Brookside Associates, LLC.  It contains original contents from the official US Navy NAVMED P-5139, but has been reformatted for web access and includes advertising and links that were not present in the original version. The medical information presented was reviewed and felt to be accurate in 2001. Medical knowledge and practice methods may have changed since that time. Some links may no longer be active. This web version has not been approved by the Department of the Navy or the Department of Defense. The presence of any advertising on these pages does not constitute an endorsement of that product or service by either the US Department of Defense or the Brookside Associates. The Brookside Associates is a private organization, not affiliated with the United States Department of Defense.

© 2015, Brookside Associates, LLC. All rights reserved

Other Brookside Products

 

 

Advertise on this site